Keros Therapeutics logo
Keros Therapeutics KROS
$ 11.04 -3.41%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

Keros Therapeutics Net Income | KROS

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Keros Therapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
87 M -187 M -153 M -105 M -58.7 M -45.4 M -12.3 M -1.34 M - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
87 M -187 M -59.5 M

Quarterly Net Income Keros Therapeutics

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
14.2 M -28.7 M -23.7 M -23.5 M -7.28 M -30.7 M 148 M -46 M -53 M -45.3 M -43.1 M -40.2 M -39.4 M -37.5 M -35.8 M -29.7 M -23.5 M -27.3 M -24.2 M -6.94 M -20.3 M -15.6 M -15.9 M -9.66 M -12 M -11 M -12.7 M - -3.55 M -2.85 M -3.18 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
148 M -53 M -17 M

References

  1. Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer Net Income Price % 24h Market Cap Country
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
-65.8 M $ 7.42 -2.37 % $ 203 M israelIsrael
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
287 M $ 14.7 -1.28 % $ 1.98 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-288 M $ 0.91 -6.96 % $ 242 M britainBritain
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
-158 M $ 3.97 0.89 % $ 324 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
-183 M $ 129.32 -4.69 % $ 6.43 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
-733 M $ 75.96 -2.84 % $ 14.5 B usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
264 M $ 7.23 -1.3 % $ 1.52 B usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
-219 M $ 2.89 -5.25 % $ 200 M britainBritain
Benitec Biopharma Benitec Biopharma
BNTC
-45.7 M $ 7.95 -2.4 % $ 370 M usaUSA
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
-32.8 M $ 8.24 2.74 % $ 387 M usaUSA
Insmed Incorporated Insmed Incorporated
INSM
-1.28 B $ 141.06 -2.35 % $ 28.1 B usaUSA
Iovance Biotherapeutics Iovance Biotherapeutics
IOVA
-391 M $ 6.9 -5.61 % $ 2.47 M usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
-11.5 M $ 4.64 17.17 % $ 56.6 M israelIsrael
InMed Pharmaceuticals InMed Pharmaceuticals
INM
-12.6 M $ 15.56 13.57 % $ 64.8 M canadaCanada
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
-847 M $ 12.36 -9.55 % $ 799 M usaUSA
Immutep Limited Immutep Limited
IMMP
-61.4 M $ 3.11 -9.06 % $ 4.53 B australiaAustralia
Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc
JAZZ
-356 M $ 228.26 -3.46 % $ 13.9 B irlandaIrlanda
BeyondSpring BeyondSpring
BYSI
-1.01 M $ 0.33 -24.42 % $ 13.6 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
-168 M $ 0.94 -7.24 % $ 94.5 M usaUSA
Johnson & Johnson Johnson & Johnson
JNJ
26.8 B $ 270.2 1.18 % $ 650 B usaUSA
Cue Biopharma Cue Biopharma
CUE
-26.6 M $ 4.2 -6.67 % $ 398 M usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
-105 M $ 2.49 1.84 % $ 206 M usaUSA
Codexis Codexis
CDXS
-44 M $ 1.0 -5.17 % $ 87.1 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
20.2 M $ 7.75 -1.02 % $ 447 M israelIsrael
Compugen Ltd. Compugen Ltd.
CGEN
35.3 M $ 1.83 -2.66 % $ 171 M israelIsrael
Coherus BioSciences Coherus BioSciences
CHRS
168 M $ 0.37 -4.06 % $ 43.3 M usaUSA
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
-174 M $ 3.06 2.68 % $ 111 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
-259 M $ 27.36 -2.15 % $ 1.82 B usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
-67.6 M $ 0.9 -9.7 % $ 90.3 M franceFrance
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
-63.5 M $ 0.78 -4.87 % $ 179 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
-7.19 M $ 2.01 -7.59 % $ 11.4 M usaUSA
Eli Lilly and Company Eli Lilly and Company
LLY
20.6 B $ 1 345.4 -0.44 % $ 1.21 T usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
63 M $ 24.73 -1.9 % $ 783 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
-7.83 M $ 0.32 1.02 % $ 2.52 M israelIsrael
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
-78.5 M $ 2.05 -15.81 % $ 27.3 M usaUSA
Forte Biosciences Forte Biosciences
FBRX
-69.4 M $ 76.99 0.03 % $ 997 M usaUSA
Curis Curis
CRIS
-7.58 M $ 0.44 -6.31 % $ 5.79 M usaUSA
CorMedix CorMedix
CRMD
163 M $ 5.25 4.23 % $ 378 K usaUSA
Larimar Therapeutics Larimar Therapeutics
LRMR
-166 M $ 3.07 -4.66 % $ 255 M usaUSA
Champions Oncology Champions Oncology
CSBR
-1.18 M $ 4.34 -1.36 % $ 60 M usaUSA
Mesoblast Limited Mesoblast Limited
MESO
-102 M $ 10.9 -2.5 % $ 13.2 B australiaAustralia
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
-23.4 M $ 96.15 0.67 % $ 4.83 B usaUSA
MannKind Corporation MannKind Corporation
MNKD
5.86 M $ 3.85 -2.66 % $ 1.18 B usaUSA
Dyadic International Dyadic International
DYAI
-7.36 M $ 0.29 -6.53 % $ 10.5 M usaUSA
Merck & Co. Merck & Co.
MRK
18.3 B $ 133.34 0.4 % $ 334 B usaUSA
Moderna Moderna
MRNA
-2.82 B $ 195.25 -2.05 % $ 76 B usaUSA
NuCana plc NuCana plc
NCNA
-29.4 M $ 0.75 4.39 % $ 8.42 B britainBritain
Novartis AG Novartis AG
NVS
14 B $ 150.51 -0.47 % $ 292 B schweizSchweiz
Puma Biotechnology Puma Biotechnology
PBYI
31.1 M $ 7.05 -1.05 % $ 353 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
-26.2 M $ 3.69 -0.67 % $ 281 M usaUSA